You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華領醫藥-B(02552.HK)公佈上半年業績:成功完成關鍵III期單藥臨牀試驗 III期聯合用藥臨牀試驗達到24周主要療效終點
格隆匯 08-17 16:16

格隆匯8月17日丨華領醫藥-B(02552.HK)公佈,截至2020年6月30日止6個月,除税前虧損較截至2019年6月30日止6個月減少約6200萬元人民幣(單位下同)或約26.3%至約1.73億元;期內虧損及全面開支總額較截至2019年6月30日止6個月減少約6180萬元或約26.3%至約1.74億元。

截至2020年6月30日止6個月,產生開支總額約1.80億元,其中約1.12億元為研發開支;研發開支較截至2019年6月30日止6個月減少約5430萬元或約32.6%至約1.12億元。截至2020年6月30日,銀行結餘及現金為約9.50億元。

截至2020年6月30日止6個月,公司發佈了HMM0110、HMM0111及HMM0112 I期試驗的正面結果,以及公司在中國其中一項重要III期註冊試驗(SEED/HMM0301)的首個52周研究正面結果。於2020年7月1日,公司發佈dorzagliatin與二甲雙胍聯合用藥III期試驗(DAWN/HMM0302)的首個24周研究正面結果。

公司亦於美國糖尿病協會第80屆科學年會上展示β細胞功能改善的數據,有關數據乃建基於公司核心研究的正面結果。有關結果顯示dorzagliatin對T2D患者具有恢復葡萄糖穩態平衡的潛力,並且對公司推動dorzagliatin成為T2D治療基礎療法的工作繼續發揮支持作用。公司繼續進行III期註冊試驗DAWN/HMM0302,預期於2020年第三季或之前完成52周研究,並於2020年年底前公佈核心研究結果。

公司亦正在中國持續進行一項I期試驗(HMM0109),研究dorzagliatin對肝功能受損患者的藥代動力學影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account